Circular RNA–based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer
Proceedings of the National Academy of Sciences · 06.01.2026 · 123 (1)
DOI: 10.1073/pnas.2504904123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 30.12.2025. Verfasst von Yudong Lin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China. Hauptthemen laut MEDLINE: RNA, Circular, Prostatic Neoplasms, Castration-Resistant, Fatty Acids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Joint construction project of Zhejiang Province and Ministry, The "Pioneer" and "Leading Goose" R&D Program of Zhejiang Province.
Abstract (Originalsprache)
Androgen receptor (AR) signaling is essential for prostate cancer (PCa) cell growth and remains a key therapeutic target in castration-resistant PCa (CRPC). While circular RNAs (circRNAs) are increasingly recognized as important regulatory molecules, their roles in AR signaling during PCa progression remain poorly understood. This study identified circUTRN , an AR-inhibited circRNA that is upregulated following neoadjuvant hormonal therapy and downregulated in PCa tissues. circUTRN inhibits proliferation in both castration-sensitive and castration-resistant PCa. Mechanistically, circUTRN binds to acetyl-CoA carboxylase 1 (ACC1) and impairs the activity through both phosphorylation-dependent and independent pathways, thereby disturbing de novo fatty acid synthesis. The dynamic relation between circUTRN and ACC1 expression during PCa progression from treatment-naïve to therapeutic-resistant states highlights the metabolic vulnerability of fatty acid synthesis. Notably, we developed nanoparticles to deliver circUTRN in combination with AR signaling inhibitors (ARSIs). This approach effectively suppressed CRPC xenograft tumor growth, even in models resistant to next-generation ARSIs. This study reveals an AR-regulated circRNA involved in PCa progression and suggests a potential therapeutic strategy for treatment-resistant PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
- Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
- Department of Radiology, Sir Run Run Shaw hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
- Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University, Hangzhou 310058, China.
ORCID-Profile: Yudong Lin, Wenjing Su, Gonghui Li
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Joint construction project of Zhejiang Province and Ministry
- The "Pioneer" and "Leading Goose" R&D Program of Zhejiang Province
- The Joint Funds of the Zhejiang Provincial Natural Science Foundation of China
- The “Pioneer” and “Leading Goose” R&D Program of Zhejiang Province
Zitieren
APA
Lin, Y., Wang, R., Li, F., Lu, Z., Luo, W., Lu, H., Xu, Z., Xu, C., Lu, Y., Zhu, Z., Li, Y., Mao, X., Xia, L., Yu, X., Su, W., Ding, L., & Li, G. (2026). Circular RNA–based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer. Proceedings of the National Academy of Sciences, 123(1). https://doi.org/10.1073/pnas.2504904123
Vancouver
Lin Y, Wang R, Li F, Lu Z, Luo W, Lu H, et al. Circular RNA–based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer. Proceedings of the National Academy of Sciences. 2026;123(1). doi:10.1073/pnas.2504904123
BibTeX
@article{Lin2026,
author = {Lin, Yudong and Wang, Ruyue and Li, Fan and Lu, Zeyi and Luo, Wenqin and Lu, Haohua and Xu, Zhehao and Xu, Chang and Lu, Yi and Zhu, Ziwei and Li, Yang and Mao, Xudong and Xia, Liqun and Yu, Xiaojing and Su, Wenjing and Ding, Lifeng and Li, Gonghui},
title = {Circular RNA–based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {1},
doi = {10.1073/pnas.2504904123}
}
EUVIMED